Financial Shenanigans

The Forensic Verdict

Centene is a 52 / Elevated on the forensic risk scale. The reported numbers are not obviously manipulated, and the $6.7B FY2025 goodwill write-down is consistent with a real and disclosed deterioration in Marketplace and Medicaid economics. But three structural patterns deserve underwriting: (1) earnings smoothing through prior-year medical claims reserve releases averaging roughly $2.3B per year, equal to about 70% of FY2024 net income, (2) a non-GAAP gap of $15.61 per share in FY2025 with adjusted EPS of $2.08 versus a GAAP loss of $(13.53), large even after impairments are excluded, and (3) operating cash flow that swings $7.9B between FY2023 and FY2024 and another $4.9B into FY2025, mostly explained by pharmacy rebate, risk-adjustment, and Part D timing rather than recurring conversion. The cleanest offsetting evidence is that receivables fell in FY2025 even as revenue grew 19%, and KPMG remains the auditor with no reported resignation, material weakness, or restatement. The single data point that would most change the grade is the disposition of the new February 2026 receivable purchase agreement that allows Centene to sell up to its $4.0B Part D risk-sharing receivable to a third party. If the facility is used at scale, FY2026 CFO will look stronger than the underlying business supports.

Shenanigans Scorecard - 13-category coverage

Breeding Ground

The conditions that make accounting strain more likely are mixed but not extreme. Centene has long auditor tenure (KPMG continuously since 2005), an unusually broad reserving toolkit on medical claims, and a recent Florida state Medicaid settlement that became politically charged. Counterweighting these are an independent-majority board, a professional CFO, and no admitted material weakness or restatement.

The breeding ground is a yellow watch, not a red light. Long auditor tenure plus a politically sensitive Medicaid settlement and a fresh securities class action mean external scrutiny is rising. That is the right time to harden the forensic underwriting on every judgmental account.

Earnings Quality

Earnings quality has deteriorated in two specific ways. First, the HBR has stepped from 87.7% to 91.9% in two years, a 420-basis-point compression that, on $174.6B of premium and service revenue, translates to roughly $7.3B of pre-tax pressure that Centene has only partly offset with rate increases. Second, the dependence on prior-year favorable medical claims development is becoming load-bearing for adjusted earnings.

Margin compression is the spine of the FY2025 result

The HBR step is real, disclosed, and economically driven by Marketplace morbidity, IRA-driven Part D restructuring, and Medicaid acuity. The forensic question is not whether the deterioration is genuine (it is) but whether prior-period HBRs were artificially low because of over-reserving that subsequently developed favorably. The disclosed favorable development tells that story.

Releasing 12 to 14% of the opening medical claims reserve each year is consistent with management's stated "moderately adverse" reserving policy, but it is also a reliable contribution to GAAP earnings of roughly $2.3B per year. In a year where adjusted earnings before tax was approximately $1.4B (Adj EPS $2.08 on 491M shares grossed at the disclosed 20.4% tax rate), the favorable development is larger than the entire adjusted profit pool.

Receivables vs revenue: stress in 2024, reversal in 2025

The FY2024 spike in DSO from 36.8 to 44.1 days is explained but not innocuous. Management has pinned it on the January 2024 transition to a third-party PBM and on Marketplace risk-adjustment timing. Both are real, but both also represent a multi-billion-dollar bridge between the income statement and the cash-flow statement. The reversal to 33.9 days in FY2025 is the strongest clean signal in the file - receivables fell 8% while revenue rose 19%, which is the opposite of revenue manipulation.

Big-bath impairments are recurring, not one-time

Three of the last four years have included impairment charges that management excludes from adjusted EPS. FY2023 stacked Circle Health ($292M), Operose Health ($140M), and real estate ($105M); FY2025 stacked goodwill ($6,723M), Magellan Health ($513M), intangibles ($55M), and real estate ($20M). Calling each of these "non-recurring" is a stretch when the recurrence rate is roughly two years out of every three.

Cash Flow Quality

Operating cash flow is highly volatile and increasingly dependent on working-capital reversals and timing. The volatility is honestly disclosed but the magnitude is large enough to undermine any one-year valuation that uses CFO or FCF directly.

The chart shows three things at once. First, CFO is structurally lumpier than reported earnings, driven by reserve build/release, pharmacy rebate timing, risk-adjustment settlements, and CMS Part D risk-sharing flows that all settle over multi-quarter windows. Second, FY2024 was effectively a zero-CFO year even though management reported $3.3B of net income and $7.17 of adjusted EPS. Third, FY2025 free cash flow of $4.3B against a GAAP net loss of $6.7B is the single largest divergence in the dataset.

What is actually inside FY2025 operating cash flow

Roughly $4.4B of FY2025 CFO is the reversal of pharmacy rebate / receivables drag plus medical claims liability build, against $1.8B of operating cash income (net loss plus non-cash impairments and D&A, less true working capital drag). The medical claims liability rose to $20.5B at year-end, up from $18.3B, even though days in claims payable fell from 53 to 46. That means the liability grew because of membership and cost growth, not because Centene was paying providers more slowly. That is a healthier read than first appears, but it is still a one-off recovery from the FY2024 PBM transition.

Days in claims payable: 53 to 46 in one year

Days in claims payable falling 7 days in one year is a yellow flag for two reasons. First, it suggests the medical claims reserve is keeping less cushion relative to current cost run-rate. Second, in dollar terms a 7-day reduction at FY2025 cost run-rate is roughly $3.0B of reserve "thinness", and management's own sensitivity disclosure shows that a 1% completion-factor change moves the reserve by $1.36B. Future favorable PY development from the FY2025 vintage may be smaller than the $2.3B-$2.4B run-rate of recent years.

The new accounts-receivable sale facility

The February 13, 2026 master receivable purchase agreement allows Centene to sell up to its $4.0B 2025 plan-year Part D risk-sharing receivable to a third-party purchaser at a discount priced off SOFR plus a spread. The discount will be classified as an SG&A expense, and the transfer will be accounted for as a sale of accounts receivable, not a borrowing. As of the filing date, no receivables had been sold, but the optionality is meaningful. If used in FY2026, it converts a roughly $4B receivable build into an immediate operating cash inflow. Investors should track the sold balance disclosed in any future 10-Q and adjust reported CFO downward by that amount when judging organic cash generation.

Metric Hygiene

The most aggressive forensic exposure on this name is non-GAAP definition stretch. Adjusted EPS routinely excludes large items that recur, and the FY2025 reconciliation buries the goodwill impairment, Magellan Health impairment, severance, and divestiture-related items in a single $14.86 "Other adjustments" line.

GAAP vs adjusted EPS divergence

In an ordinary year (FY2023, FY2024) the non-GAAP gap is $0.86 to $1.73, mostly amortization of acquired intangibles, which is at least an internally consistent exclusion. In FY2025 the gap is $15.61, of which $13.63 is goodwill impairment, $1.04 is Magellan, and the rest a mix of intangible/real estate write-downs and acquisition-related expenses. Excluding amortization of acquired intangibles every single year (FY2025: $1.39 per share, on $4.5B remaining intangibles) is a recurring economic cost. These are real assets being consumed.

Metric hygiene scorecard

Soft-asset and goodwill trajectory

The FY2025 goodwill drop from $17.6B to $10.8B is the long-deferred recognition of value destruction in the 2020 WellCare deal economics under the new Medicaid/Marketplace cost trend. The disclosure is clean (quantitative test, third-quarter trigger event, market multiples corroborated) but the timing is suggestive. Management took the impairment in the same quarter the stock dropped sharply and only after the OBBBA had passed. Investors should track residual goodwill ($10.8B) for further impairment risk if FY2026 Marketplace experience is worse than the refiled rates assume.

What to Underwrite Next

Centene's accounting risk is not a thesis breaker. It is a valuation haircut and a position-sizing limiter. The income statement, balance sheet, and cash-flow statement are internally consistent, the auditor is in place, no restatement has occurred, and the largest charge of the year (goodwill) is non-cash and disclosed. But the scope of management discretion in medical claims reserving, Marketplace risk-adjustment estimates, premium deficiency reserves, and non-GAAP definitions is wide enough that any single year's reported earnings can be 25 to 50% different from underlying economic earnings.

What would change the grade

Final read

The reported numbers at Centene are a reasonable, but not faithful, representation of economic reality. Reserves, risk-adjustment estimates, premium deficiency reserves, and non-GAAP exclusions each contain enough discretion that a thoughtful investor should haircut adjusted EPS by roughly 15 to 25% to remove the structural earnings cushion from prior-year reserve releases and to add back recurring "non-recurring" items like severance and small impairments. Free cash flow should be normalized at $2.5B-$3.5B per year rather than the 7-year mean of $4.0B, given how much of recent CFO has been timing-driven. None of this implies fraud or misconduct; it implies a level of accounting elasticity that turns into a 1 to 2 multiple-turn valuation discount versus a peer with cleaner cash conversion. Underwrite the position accordingly, watch the receivable purchase agreement utilization carefully, and treat the next two years of HBR and reserve disclosures as the load-bearing inputs to any thesis on this name.